TOPII-targeting and MUS81 deficiency sensitise HER2-low tumour models to T-DXd
Monypenny, J.; Savage, C.; Caipa Garcia, A. L.; Jiang, X.; Weitsman, G.; Foiani, M.; Ng, T.
Show abstract
In this study, we identify Topoisomerase II (TopII ) targeting and MUS81 deficiency as sensitisers to trastuzumab deruxtecan (T-DXd), a HER2-targeting antibody-drug conjugate with a potent topoisomerase I poison payload that is of clinical importance in the treatment of HER2 expressing solid tumours in a range of cancer types. Using preclinical tumour spheroid models of breast and colorectal cancer, we show that TopII targeting with doxorubicin sensitises HER2-low tumour cells to T-DXd, elevating cell cytotoxicity, DNA damage, and checkpoint pathway activation. T-DXd treatment, both as a single agent and in combination with doxorubicin, increases TopII expression, highlighting this nuclear endonuclease as a potential candidate biomarker for T-DXd response in both the HER2-high and HER2-low setting. Using isogenic CRISPR models, we show that genetic loss of the MUS81 structure-specific endonuclease, a key processor of branched DNA structures and under-replicated DNA, sensitises HER2-low colorectal cancer cells to T-DXd. Given that reduced expression of MUS81 is closely related to metastasis and poor prognosis in colorectal carcinoma, our findings highlight the potential utility of these treatment combinations in a subset of colorectal cancer patients that present with HER2-positve/MUS81-low disease.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells 92%
- Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer. 92%
- Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer 92%
Similar papers in this journal
- NCOR2 represses MHC class I molecule expression to drive metastatic progression of breast cancer 93%
- Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation 93%
- Single-cell Transcriptomics reveals multi-step adaptations to endocrine therapy 93%
Similar papers in this journal
- Guiding ATR and PARP inhibitor combinations with chemogenomic screens 93%
- Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors 93%
- DNA Damage Response Deficiency Enhances Neuroblastoma Progression and Sensitivity to Combination PARP and ATR Inhibition 93%
Similar papers in this journal
- Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models 93%
- Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer. 92%
- An Omic and Multidimensional Spatial Atlas from Serial Biopsies of an Evolving Metastatic Breast Cancer 92%
Similar papers in this journal
- Resilience and vulnerabilities of tumor cells under purine shortage stress 93%
- Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer 92%
- Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.